Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia drug
Biotech
LB Pharma upsizes IPO in 1st biotech listing since February
LB’s decision to break cover and go public seems to have paid off, with the company bumping up the number of shares on offer for its Nasdaq listing.
James Waldron
Sep 11, 2025 4:09am
LB Pharmaceuticals eyes $228M in IPO cash
Sep 8, 2025 3:16pm
MapLight raises $373M to plot phase 2 journey for Cobenfy rival
Jul 28, 2025 10:23am
Boehringer's schizophrenia drug fails trio of phase 3 trials
Jan 16, 2025 11:58am
LB Pharma's twist on old Sanofi drug passes schizophrenia test
Jan 8, 2025 7:00am
Neurocrine's KarXT rival hits in phase 2—but only at low dose
Aug 28, 2024 7:53am
